指南与共识消化道肿瘤与早癌消化内镜

结直肠癌筛查:美国多学会结直肠癌工作组给医生和患者的建议

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer.
指南 / 共识 · Am J Gastroenterol · 2017-06-06

美国多学会结直肠癌工作组(MSTF)更新结直肠癌筛查建议,将筛查试验按性能、成本和实用性分为三层:第一层为每10年一次结肠镜和每年一次粪便免疫化学检测(FIT),第二层为每5年一次CT结肠成像、每3年一次FIT-粪便DNA检测和每5至10年一次乙状结肠镜,第三层为每5年一次胶囊结肠镜;建议不将Septin9血清检测用于筛查。一般风险人群50岁开始筛查,非裔美国人可45岁开始;有家族史者按亲属发病年龄和人数调整筛查起始年龄与间隔。

要点

  • 第一层筛查试验为每10年一次结肠镜和每年一次FIT,二者为筛查基石。
  • 一般风险人群50岁开始筛查,非裔美国人可45岁开始。
  • 有家族史者按亲属发病年龄和人数调整筛查起始年龄与间隔。

核心结论

  • 结肠镜和FIT被推荐为筛查基石,无论筛查以何种方式提供;当提供多种选择时,二者为首选试验。
  • 可采用风险分层方法,在进展期肿瘤估计低流行人群用FIT筛查,高流行人群用结肠镜筛查。
  • 建议不将Septin9血清检测(Epigenomics,西雅图,华盛顿州)用于筛查。

研究设计与样本

  • 美国多学会结直肠癌工作组(MSTF)更新结直肠癌筛查建议,代表美国胃肠病学会、美国胃肠病协会和美国胃肠内镜学会。

主要发现

  • 第一层试验为每10年一次结肠镜和每年一次FIT;第二层试验为每5年一次CT结肠成像、每3年一次FIT-粪便DNA检测和每5至10年一次乙状结肠镜,均有相对于第一层试验的缺点。
  • 因证据有限和当前使用障碍,每5年一次胶囊结肠镜为第三层试验。
  • 50岁以下人群结直肠癌发病率上升,建议对疑似结直肠出血的年轻人进行彻底诊断评估。
  • 筛查及时且既往筛查阴性(特别是结肠镜)者达75岁或预期寿命不足10年时应考虑停止筛查;无既往筛查者可根据年龄和合并症考虑筛查至85岁。

关键数值与推荐

  • 一般风险人群50岁开始筛查,非裔美国人有限证据支持45岁开始。
  • 一级亲属<60岁患结直肠癌或进展期腺瘤,或任何年龄2名一级亲属有上述发现,推荐每5年一次结肠镜筛查,从最年轻受累亲属诊断年龄前10年或40岁开始,以较早者为准。
  • 一级亲属≥60岁 single 患结直肠癌或进展期腺瘤,可从40岁开始提供平均风险筛查选项。

临床怎么用

  • 在基于结肠镜首先提供的序贯方法中,应向拒绝结肠镜的患者提供FIT。
  • 对疑似结直肠出血的年轻人建议彻底诊断评估。
  • 对无既往筛查者,根据年龄和合并症考虑筛查至85岁。

局限性

  • 胶囊结肠镜因证据有限和当前使用障碍被列为第三层试验。
  • 非裔美国人45岁开始筛查的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This document updates the colorectal cancer (CRC) screening recommendations of the U.S. Multi-Society Task Force of Colorectal Cancer (MSTF), which represents the American College of Gastroenterology, the American Gastroenterological Association, and The American Society for Gastrointestinal Endoscopy. CRC screening tests are ranked in 3 tiers based on performance features, costs, and practical considerations. The first-tier tests are colonoscopy every 10 years and annual fecal immunochemical test (FIT). Colonoscopy and FIT are recommended as the cornerstones of screening regardless of how screening is offered. Thus, in a sequential approach based on colonoscopy offered first, FIT should be offered to patients who decline colonoscopy. Colonoscopy and FIT are recommended as tests of choice when multiple options are presented as alternatives. A risk-stratified approach is also appropriate, with FIT screening in populations with an estimated low prevalence of advanced neoplasia and colonoscopy screening in high prevalence populations. The second-tier tests include CT colonography every 5 years, the FIT-fecal DNA test every 3 years, and flexible sigmoidoscopy every 5 to 10 years. These tests are appropriate screening tests, but each has disadvantages relative to the tier 1 tests. Because of limited evidence and current obstacles to use, capsule colonoscopy every 5 years is a third-tier test. We suggest that the Septin9 serum assay (Epigenomics, Seattle, Wash) not be used for screening. Screening should begin at age 50 years in average-risk persons, except in African Americans in whom limited evidence supports screening at 45 years. CRC incidence is rising in persons under age 50, and thorough diagnostic evaluation of young persons with suspected colorectal bleeding is recommended. Discontinuation of screening should be considered when persons up to date with screening, who have prior negative screening (particularly colonoscopy), reach age 75 or have <10 years of life expectancy. Persons without prior screening should be considered for screening up to age 85, depending on age and comorbidities. Persons with a family history of CRC or a documented advanced adenoma in a first-degree relative age <60 years or 2 first-degree relatives with these findings at any age are recommended to undergo screening by colonoscopy every 5 years, beginning 10 years before the age at diagnosis of the youngest affected relative or age 40, whichever is earlier. Persons with a single first-degree relative diagnosed at ≥60 years with CRC or an advanced adenoma can be offered average-risk screening options beginning at age 40 years.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017. PMID: 28555630. doi:10.1038/ajg.2017.174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。